🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🎯🎯 finally the ASCO-SOCCER CUP is arriving!! 💪💪🔥🔥 👉 SUNDAY 1st (6.09-10.00 PM) - Registration is open until to friday May 30th 👉 I hope to see again all countries involved in last ESMO2024: Brazil,Argentina,Colombia, Portugal,Peru,UK, Ireland, Netherlands, USA,

This ASCO is definitely going to be different for me. A true honor to serve as a discussant and represent Brazil. I’ll be speaking on June 1st (and probably shivering) about the EGFR exon 20 insertions and HER2 mutations treatment scenario in NSCLC after the talks of Herbert Loong, MBBS, FASCO

#ASCO25 pro tip— Free Metra tickets from McCormick to Millenium Park are back for 2025 and this year they are digital. Stop by the Metra desk on level 2.5 with any questions. tinyurl.com/49w4nmxk

I am very honored to be nominated for Director of Membership of ESMO - Eur. Oncology Election. 😊 the President’s call: #ESMOMembers vote for leaders who’ll shape ESMO’s future. Vote for Directors of Education, Public Policy & Membership , and Chair and members of the Nomination Committee

Treinando pra corrida amanhã Time Brasil 🇧🇷 Vladmir C. Cordeiro de Lima, MD, PhD Gil-Santana OncoAlert #OncoAlertAF

Living a dream: my first time at #ASCO2025 Honored to present our research on sexual dysfunction in men with cancer before systemic treatment, alongside Vladmir C. Cordeiro de Lima, MD, PhD Let’s go! #Oncology #CancerResearch

#ASCO25 Gil-Santana OncoAlert Augusto Takao #teambrazil +30 🏃🏿 ASCO

#ASCO25 Many new drugs ➡️ welcome but marginal gains. 💰 Cost + ☣️ toxicity Exercise ➡️ marginal cost + negligible toxicity ✅ Evidence based intervention should be added to standard treatment recommendations No need to wait for regulatory approval! Do it now!

It’s THYME! Dr. Girard presents the NIVOTHYM trial. Nivo 240 q2w + Ipi 1mg/kg q6w. 51 pts treated, 14 B3, 37 TC. mPFS 3.1 mo, mDoR 7.1 mo. Significant adverse events. Thymic tumors seem to not need more IO. It’s a question of whether they respond to anti-PD-1s, or not. #ASCO25

❓Curious about visa info for hematology oncology fellowship programs? Scan the QR code to explore program details! So honored to share the results at #ASCO25 IMGCoP and great work done by the VAM committee Lei Deng, MD (He/Him) Masood Pasha Syed MBBS MD IMG Oncologists

😊⚽️😊 #ASCO2025 One year more the ASCO-SOCCER Cup was a success!! Toni Choueiri, MD Amazing and beautiful time sharing with a lot of friends! Thanks to Eric J. Small, MD, FASCO for official ASCO open tournament and all players 🇧🇷🇨🇴🇺🇸🇦🇷!!👏👏🙌🙌 👉 the ESMO-SOCCER cup 2025 is on the way! Please

🕒 Timing matters in #NSCLC ICI ASCO RCT shows early-day immunochemotherapy (before 15:00) nearly doubled outcomes vs late: 🔹 mPFS: 11.3m vs 5.7m (HR 0.42) 🔹 mOS: NR vs 16.4m (HR 0.45) 🔹 ORR: 75% vs 56% ToD (Time of Day) could be a game changer. #ASCO2025 #lcsm #nsclc

#ASCO25 If you don’t know where to go, just walk over to the posters section, you will always learn something new or new perspective on #cancerresearch #conferencing ASCO

#ASCO25 The X-Men Study 🇧🇷 73 men with solid tumors, 22.2% had moderate/severe sexual dysfunction before systemic therapy, despite normal hormone levels. Common issues: low desire, premature ejaculation & ED. Vladmir C. Cordeiro de Lima, MD, PhD, Mario Machado, Aldo L. A. DETTINO OncoAlert, OncoDaily

🚨NeoADAURA: Neoadjuvant osimertinib ± chemotherapy significantly improves MPR in resectable EGFRm NSCLC ASCO 🎯 MPR rates: •Osi + chemo: 26% •Osi monotherapy: 25% •Chemo alone: 2% ⚖️ OR ~19 vs control (p<0.0001) 📈 EFS immature but trending favorably #EGFR #nsclc #lcsm

Excellent summary slides for current evidence for pancreatic cancer treatment . Useful for quick reference. @asco #asco25 taken from talk by Dr Brian Wolpin 👍OncoAlert ONCO BRUNO

Congratulations to Dr. Rachel Riechelmann on being elected as ESMO Director of Membership starting January 2026! 🎉 I was lucky to have her as my mentor during my oncology residency — an inspiring leader and brilliant oncologist.

“A prevalência de disfunção sexual moderada a completa foi de 22,2% nesta coorte, taxa superior à observada na população masculina brasileira em geral”, destacam os pesquisadores. Leia mais: tinyurl.com/2pmrbass ASCO Vladmir C. Cordeiro de Lima, MD, PhD Gil-Santana

1/3 🫁 #Afatinib vs Chemotherapy with #Uncommon #EGFR Mutations: ACHILLES/TORG1834 ⭐️ Final OS analysis #ASCO25 Abstract #8623 #egfr #LCSM #uncommon #compound #afatinib

#ASCO25 Ed Book: From Africa, India 🇮🇳 & LATAM Brasil 🇧🇷 and México 🇲🇽, proposals to improve global cancer care for all patients. ascopubs.org/doi/pdfdirect/… Regina Barragan-Carrillo Rodrigo Dienstmann_MD_MBA Frederick Chite MD FASCO Dr Dinesh Pendharkar MD PhD FASCO Instituto Nacional de Cancerología ASCO